The on-body injector's fixed, flat-rate dosage simplifies clinical workflow and improves safety by eliminating the need for constant, error-prone dose recalculations based on patient weight changes, which is standard for many body surface area (BSA)-based cancer therapies.
Related Insights
While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.
Administering complex biologics at home via on-body devices can bridge significant healthcare disparities. This model can eliminate the physical, financial, and geographic barriers faced by patients in rural areas or those reliant on caregivers for transport to infusion centers.
The rapid and successful rollout of complex bispecific therapies into community settings is primarily driven by enhanced nursing staff skills and protocols for risk stratification. This combination allows for safe outpatient administration, preventing hospital admissions and broadening patient access beyond large academic centers.
A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.
Subcutaneous on-body device delivery of anti-CD38 antibodies like isatuximab nearly eliminates the high risk of infusion-related reactions common with intravenous administration, especially during the first dose. This significantly enhances patient safety and comfort in the clinic.
Beyond the initial wave of GLP-1s from Novo and Lilly, the next major competitive front in the obesity market will be monthly injectables. Amgen and Pfizer (via its Metsara acquisition) are poised to lead this race, shifting the focus to dosing convenience and long-term adherence.
A major challenge in managing high cholesterol is patient adherence to daily medication for life. New therapies like Inclisiran use mRNA silencing and require only two injections per year, dramatically improving adherence for busy or non-compliant individuals.
Despite being a pill, oral Wegovy requires an empty stomach, only 4oz of water, and a 30-minute post-dose fast. This difficult regimen is a major impediment to its uptake, particularly in the U.S. where patients prioritize the maximum efficacy of injectables over the supposed convenience of a cumbersome pill.
Recent FDA approvals for Milestone's Cardamist nasal spray and J&J's subcutaneous Ribrevent Fastpro highlight a key industry trend: improving patient convenience. These products shift treatment from clinical settings to on-demand, at-home use or reduce administration time, creating value beyond just clinical efficacy.
Instead of competing on price, MYQORZO differentiates from its predecessor (BMS's Kamsiyos) with a "lighter" FDA-mandated safety program (REMS). This addresses key physician pain points like dosing flexibility and eliminating monthly pharmacy checks, aiming to boost adoption by improving the user experience.
